Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma - PubMed (original) (raw)

. 2003 Nov 1;21(21):3940-7.

doi: 10.1200/JCO.2003.05.013. Epub 2003 Sep 15.

Affiliations

• PMID: 12975461
• DOI: 10.1200/JCO.2003.05.013

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

Wen-Kai Weng et al. J Clin Oncol. 2003.

Abstract

Purpose: Although rituximab is now routinely used in the treatment of B-cell non-Hodgkin's lymphoma, the mechanism of its antitumor effect is not clear. One potential mechanism of action involves antibody-dependent cellular cytotoxicity (ADCC). Two aspects of ADCC influence the effectiveness of this process: the susceptibility of tumor cells and the activation of effector cells via their immunoglobulin G fragment C receptors (Fc gamma Rs). Several Fc gamma R polymorphisms have been identified that may affect the killing function of natural killer cells and macrophages.

Patients and methods: The pretreatment tumor cells from 43 patients with follicular lymphoma were tested for their intrinsic susceptibility to rituximab-mediated ADCC. In addition, the Fc gamma RIIIa (CD16) and Fc gamma RIIa (CD32) polymorphisms were determined in an expanded group of 87 patients. The results were then correlated with clinical outcome of these patients.

Results: No difference was found between the susceptibility of tumors from patients who clinically responded to rituximab versus those who did not respond. Conversely, both the Fc gamma RIIIa 158 valine/valine and the Fc gamma RIIa 131 histidine/histidine genotypes were found to be independently associated with the response rate and freedom from progression.

Conclusion: These data support the hypothesis that ADCC plays an important role in the clinical effect of rituximab at the level of the effector cell. It will be important to include information on Fc receptor polymorphisms in future trials of rituximab therapy.

PubMed Disclaimer

Similar articles

• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
  Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. Musolino A, et al. J Clin Oncol. 2008 Apr 10;26(11):1789-96. doi: 10.1200/JCO.2007.14.8957. Epub 2008 Mar 17. J Clin Oncol. 2008. PMID: 18347005
• A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
  Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA. Khan KD, et al. Clin Cancer Res. 2006 Dec 1;12(23):7046-53. doi: 10.1158/1078-0432.CCR-06-1571. Clin Cancer Res. 2006. PMID: 17145827 Clinical Trial.
• Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
  Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Treon SP, et al. J Clin Oncol. 2005 Jan 20;23(3):474-81. doi: 10.1200/JCO.2005.06.059. J Clin Oncol. 2005. PMID: 15659493 Clinical Trial.
• The therapeutic use of rituximab in non-Hodgkin's lymphoma.
  Marcus R, Hagenbeek A. Marcus R, et al. Eur J Haematol Suppl. 2007 Jan;(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x. Eur J Haematol Suppl. 2007. PMID: 17206982 Review.
• Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden.
  Solal-Céligny P. Solal-Céligny P. Anticancer Drugs. 2001 Jun;12 Suppl 2:S11-4. Anticancer Drugs. 2001. PMID: 11508931 Review.

Cited by

• Mechanisms of Resistance to Rituximab Used for the Treatment of Autoimmune Blistering Diseases.
  Popa LG, Dumitras I, Giurcaneanu C, Berghi O, Radaschin DS, Vivisenco CI, Popescu MN, Beiu C. Popa LG, et al. Life (Basel). 2024 Sep 25;14(10):1223. doi: 10.3390/life14101223. Life (Basel). 2024. PMID: 39459523 Free PMC article. Review.
• One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa/CD16a structure.
  Kremer PG, Lampros EA, Blocker AM, Barb AW. Kremer PG, et al. Elife. 2024 Oct 25;13:RP100083. doi: 10.7554/eLife.100083. Elife. 2024. PMID: 39453384 Free PMC article.
• A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide.
  Yang G, Nikkhoi SK, Owji H, Li G, Massumi M, Cervelli J, Vandavasi VG, Hatefi A. Yang G, et al. Antibodies (Basel). 2024 Sep 10;13(3):75. doi: 10.3390/antib13030075. Antibodies (Basel). 2024. PMID: 39311380 Free PMC article.
• FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population.
  Constantinides M, Robert N, Multrier C, Coënon L, Campos-Mora M, Jacquard C, Gao F, Zemiti S, Presumey J, Cartron G, Moreaux J, Villalba M. Constantinides M, et al. Oncoimmunology. 2024 Aug 18;13(1):2388306. doi: 10.1080/2162402X.2024.2388306. eCollection 2024. Oncoimmunology. 2024. PMID: 39175948 Free PMC article.
• Cancer immunotherapies: A hope for the uncurable?
  Hamdan F, Cerullo V. Hamdan F, et al. Front Mol Med. 2023 Feb 17;3:1140977. doi: 10.3389/fmmed.2023.1140977. eCollection 2023. Front Mol Med. 2023. PMID: 39086690 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Pharmacogenomics Knowledge Base

• Miscellaneous

  • NCI CPTAC Assay Portal